Blood pressure targets: Are clinical guidelines wrong?

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 350-354

  Arguedas, José Agustín ^a,b  

^a UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^b Hospital Clinica Biblica   (Costa Rica)

Author keywords

blood pressure; hypertension; targets

Indexed keywords

INDAPAMIDE PLUS PERINDOPRIL; RAMIPRIL; TELMISARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DIASTOLE; EVIDENCE-BASED MEDICINE; GOALS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SYSTOLE;

EID: 77953807515     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32833a6dee     Document Type: Review

References (36)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003; 42:1206-1252.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
5. Graham I, Atar D, Borch-Jonsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28:2375-2414.
6. Littlejohns P, Ranson P, Sealey C, et al. for the National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care (partial update of NICE Clinical Guideline 18). National Institute for Health and Clinical Excellence. www.nice.org.uk/page.aspx?o=278167 (accessed 25 March 2010).
7. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans. Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163:525-541.
8. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-2788.
9. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010; 33(Suppl 1):S11-S61.
10. Laurent S. Guidelines from the British Hypertension Society. The lower the pressure the better. BMJ 2004; 328:593-594.
11. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
12. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009; CD004349. doi: 10.1002/14651858.CD004349.pub2.
13. Toto RD, Mitchell HC, Smith RD, et al. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48:851-859.
14. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
15. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2):B54-B64.
16. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
17. Ruggenenti P, Perna A, Loriga G, et al., for the REIN-2 Study Group. Bloodpressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomized, controlled trial. Lancet 2005; 365:939-946.
18. Peterson JC, Adler S, Burkart JM, et al., for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123:754-762.
19. Wright JT, Bakris G, Greene T, et al., for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. JAMA 2002; 288:2421-2431.
20. Arguedas JA, Leiva V, Wright JM. Blood pressure targets for hypertension in patients with diabetes mellitus (Protocol). Cochrane Database Syst Rev 2010; CD008277. doi: 10.1002/14651858.CD008277.
21. JATOS Study Group. Principal results of the Japanese Trial to AssessOptimal Systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115-2127.
22. Verdecchia P, Staessen JA, Angeli F, et al. Usual versus tight control of systolic blood pressure in nondiabetic patients with hypertension (Cardio- Sis): an open-label randomised trial. Lancet 2009; 374:525-533.
23. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (in press).
24. Solomon SD, Verma A, Desai A, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010; 55:241-248.
25. Gueyffier F. Observational epidemiological studies: values and limitations. J Hypertens 2001; 21:673-675.
26. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-462. (Pubitemid 32156151)
27. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27:1509-1520.
28. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370:829-840.
29. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
30. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
31. The Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND investigators). Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372:1174-1183.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
33. Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393. (Pubitemid 36159355)
34. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. JAMA 2008; 299:1678-1689.
35. Banegas JR, Messerli FH, Waeber B, et al. Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med 2009; 122:1136-1141.
36. Giles TD. Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich) 2009; 11:611-614.